HealthEquity (NASDAQ: HQY) reported Q4 EPS of $0.39, $0.04 better than the analyst estimate of $0.35. Revenue for the quarter came in at $201.2 versus the consensus estimate of $199.26 million.

GUIDANCE:

HealthEquity sees FY2021 EPS of $1.70-$1.81, versus the consensus of $1.80. HealthEquity sees FY2021 revenue of $770-790 million, versus the consensus of $821.5 million.

• For the fiscal year ending January 31, 2021, we expect our revenue to be between $770 million and $790 million. Our outlook for net loss is a range of $14 million to $4 million, resulting in a net loss per diluted share range of $0.19 to $0.05. Our Adjusted EBITDA outlook is a range of $245 million to $255 million. We also expect our non-GAAP net income, calculated using the updated method described below, to be in a range between $124 million and $132 million. Our non-GAAP net income outlook, results in a non-GAAP net income per diluted share range between $1.70 and $1.81 (based on an estimated 73 million weighted-average shares outstanding).

For earnings history and earnings-related data on HealthEquity (HQY) click here.